vs
富兰克林电气（FELE）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是富兰克林电气的1.1倍（$540.7M vs $500.4M），富兰克林电气净利率更高（6.9% vs -2.9%，领先9.8%），富兰克林电气同比增速更快（9.9% vs -14.1%），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -4.0%）
富兰克林电气是全球知名的水务与能源管理产品及系统制造分销商，主营泵类、电机、驱动器及控制设备，产品广泛应用于住宅、商用、农业、工业、市政等多元场景。公司总部位于美国印第安纳州韦恩堡，在美国、德国、捷克、意大利、土耳其、墨西哥、巴西、澳大利亚、南非等多个国家设有生产基地，为全球客户提供可靠的流体运输与能源管理解决方案。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
FELE vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.1倍
$500.4M
营收增速更快
FELE
高出24.1%
-14.1%
净利率更高
FELE
高出9.8%
-2.9%
两年增速更快
ICUI
近两年复合增速
-4.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $500.4M | $540.7M |
| 净利润 | $34.7M | $-15.7M |
| 毛利率 | 35.0% | 37.5% |
| 营业利润率 | 9.6% | 1.0% |
| 净利率 | 6.9% | -2.9% |
| 营收同比 | 9.9% | -14.1% |
| 净利润同比 | 10.6% | 34.0% |
| 每股收益（稀释后） | $0.77 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FELEICUI
| Q1 26 | $500.4M | — | ||
| Q4 25 | $506.9M | $540.7M | ||
| Q3 25 | $581.7M | $537.0M | ||
| Q2 25 | $587.4M | $548.9M | ||
| Q1 25 | $455.2M | $604.7M | ||
| Q4 24 | $485.7M | $629.8M | ||
| Q3 24 | $531.4M | $589.1M | ||
| Q2 24 | $543.3M | $596.5M |
净利润FELEICUI
| Q1 26 | $34.7M | — | ||
| Q4 25 | $39.3M | $-15.7M | ||
| Q3 25 | $16.7M | $-3.4M | ||
| Q2 25 | $60.1M | $35.3M | ||
| Q1 25 | $31.0M | $-15.5M | ||
| Q4 24 | $33.7M | $-23.8M | ||
| Q3 24 | $54.6M | $-33.0M | ||
| Q2 24 | $59.1M | $-21.4M |
毛利率FELEICUI
| Q1 26 | 35.0% | — | ||
| Q4 25 | 33.8% | 37.5% | ||
| Q3 25 | 35.9% | 37.4% | ||
| Q2 25 | 36.1% | 37.9% | ||
| Q1 25 | 36.0% | 34.7% | ||
| Q4 24 | 33.8% | 36.1% | ||
| Q3 24 | 35.7% | 34.8% | ||
| Q2 24 | 36.8% | 34.8% |
营业利润率FELEICUI
| Q1 26 | 9.6% | — | ||
| Q4 25 | 10.2% | 1.0% | ||
| Q3 25 | 14.6% | 2.6% | ||
| Q2 25 | 15.0% | 1.9% | ||
| Q1 25 | 9.7% | 2.1% | ||
| Q4 24 | 8.9% | 6.0% | ||
| Q3 24 | 13.8% | 1.4% | ||
| Q2 24 | 14.6% | 1.3% |
净利率FELEICUI
| Q1 26 | 6.9% | — | ||
| Q4 25 | 7.7% | -2.9% | ||
| Q3 25 | 2.9% | -0.6% | ||
| Q2 25 | 10.2% | 6.4% | ||
| Q1 25 | 6.8% | -2.6% | ||
| Q4 24 | 6.9% | -3.8% | ||
| Q3 24 | 10.3% | -5.6% | ||
| Q2 24 | 10.9% | -3.6% |
每股收益（稀释后）FELEICUI
| Q1 26 | $0.77 | — | ||
| Q4 25 | $0.87 | $-0.63 | ||
| Q3 25 | $0.37 | $-0.14 | ||
| Q2 25 | $1.31 | $1.43 | ||
| Q1 25 | $0.67 | $-0.63 | ||
| Q4 24 | $0.73 | $-0.97 | ||
| Q3 24 | $1.17 | $-1.35 | ||
| Q2 24 | $1.26 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.4M | — |
| 总债务越低越好 | $134.4M | — |
| 股东权益账面价值 | $1.3B | $2.1B |
| 总资产 | $2.0B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.10× | — |
8季度趋势，按日历期对齐
现金及短期投资FELEICUI
| Q1 26 | $80.4M | — | ||
| Q4 25 | $99.7M | — | ||
| Q3 25 | $102.9M | — | ||
| Q2 25 | $104.6M | — | ||
| Q1 25 | $84.0M | — | ||
| Q4 24 | $220.5M | $308.6M | ||
| Q3 24 | $106.3M | $312.5M | ||
| Q2 24 | $58.1M | $302.6M |
总债务FELEICUI
| Q1 26 | $134.4M | — | ||
| Q4 25 | $135.2M | — | ||
| Q3 25 | $135.2M | — | ||
| Q2 25 | $14.5M | — | ||
| Q1 25 | $14.9M | — | ||
| Q4 24 | $11.6M | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | $87.2M | — |
股东权益FELEICUI
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $2.1B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $1.2B | $2.0B |
总资产FELEICUI
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $4.1B | ||
| Q3 25 | $2.0B | $4.1B | ||
| Q2 25 | $2.0B | $4.1B | ||
| Q1 25 | $1.9B | $4.2B | ||
| Q4 24 | $1.8B | $4.2B | ||
| Q3 24 | $1.8B | $4.3B | ||
| Q2 24 | $1.8B | $4.3B |
负债/权益比FELEICUI
| Q1 26 | 0.10× | — | ||
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流FELEICUI
| Q1 26 | — | — | ||
| Q4 25 | $104.2M | $60.6M | ||
| Q3 25 | $102.7M | $56.7M | ||
| Q2 25 | $51.5M | $11.2M | ||
| Q1 25 | $-19.5M | $51.3M | ||
| Q4 24 | $110.3M | $40.2M | ||
| Q3 24 | $116.1M | $36.1M | ||
| Q2 24 | $36.4M | $82.0M |
自由现金流FELEICUI
| Q1 26 | — | — | ||
| Q4 25 | $88.7M | $36.0M | ||
| Q3 25 | $91.3M | $27.6M | ||
| Q2 25 | $39.9M | $-8.5M | ||
| Q1 25 | $-26.3M | $36.7M | ||
| Q4 24 | $97.5M | $16.1M | ||
| Q3 24 | $106.6M | $16.2M | ||
| Q2 24 | $26.1M | $62.5M |
自由现金流率FELEICUI
| Q1 26 | — | — | ||
| Q4 25 | 17.5% | 6.6% | ||
| Q3 25 | 15.7% | 5.1% | ||
| Q2 25 | 6.8% | -1.5% | ||
| Q1 25 | -5.8% | 6.1% | ||
| Q4 24 | 20.1% | 2.6% | ||
| Q3 24 | 20.1% | 2.7% | ||
| Q2 24 | 4.8% | 10.5% |
资本支出强度FELEICUI
| Q1 26 | — | — | ||
| Q4 25 | 3.1% | 4.6% | ||
| Q3 25 | 2.0% | 5.4% | ||
| Q2 25 | 2.0% | 3.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 2.6% | 3.8% | ||
| Q3 24 | 1.8% | 3.4% | ||
| Q2 24 | 1.9% | 3.3% |
现金转化率FELEICUI
| Q1 26 | — | — | ||
| Q4 25 | 2.65× | — | ||
| Q3 25 | 6.14× | — | ||
| Q2 25 | 0.86× | 0.32× | ||
| Q1 25 | -0.63× | — | ||
| Q4 24 | 3.28× | — | ||
| Q3 24 | 2.13× | — | ||
| Q2 24 | 0.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FELE
暂无分部数据
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
